Yayın:
The evaluation of oxidative stress parameters in breast and colon cancer

dc.contributor.authorKundaktepe, Berrin Papila
dc.contributor.authorSozer, Volkan
dc.contributor.authorDurmus, Sinem
dc.contributor.authorKocael, Pinar Cigdem
dc.contributor.authorKundaktepe, Fatih Orkun
dc.contributor.authorPapila, Cigdem
dc.contributor.authorGelisgen, Remise
dc.contributor.authorUzun, Hafize
dc.date.accessioned2026-06-27T14:38:34Z
dc.date.issued2021
dc.description.abstractOur aim in this study was to investigate the relationship between serum ischemia modified albumin (IMA) levels with oxidative stress parameters [protein carbonyl (PCO), advanced protein oxidation products (AOPPs), malondialdehyde (MDA), total nitric oxide (NOx), prooxidant-antioxidant balance (PAB), and ferric reducing of antioxidant power (FRAP)] in breast cancer (BC) and colon cancer (CC). In total, 90 patients undergoing surgical treatment for BC (n = 45) or CC (n = 45) and 35 healthy controls were included in this cross-sectional study. The serum PCO, AOPPs, MDA, NOx, PAB, and IMA levels were all statistically significantly higher in the cancer patients than in the control group. MDA, NOx, and PAB levels were significantly lower in the BC group than in the CC group. FRAP values were statistically significantly lower in both the CC group and the BC group compared to the control. IMA showed a weak positive correlation with CA-19.9 (r = 0.423 P = .007) but a moderate positive correlation with tumor size in the CC group. IMA showed a positive correlation with metastasis, grade, and HER2 and a negative correlation with ER and PR in the BC group. Oxidative stress is a key player in the development of solid malignancies. Cancer development is a multistage process, and oxidative stress caused by the production of ROS/RNS in the breast and colon may predispose individuals to BC and CC. Patients with BC and CC had an impaired oxidative/antioxidant condition that favored oxidative stress. The ROC analysis indicated that IMA sensitivity above 80% could be used as a secondary biomarker in diagnosis.en
dc.description.urihttps://doi.org/10.1097/md.0000000000025104
dc.identifier.doi10.1097/md.0000000000025104
dc.identifier.eissn1536-5964
dc.identifier.issn0025-7974
dc.identifier.issue11
dc.identifier.pubmed33725987
dc.identifier.urihttps://hdl.handle.net/20.500.14981/63010
dc.identifier.volume100
dc.identifier.wos000659055900068
dc.language.isoeng
dc.publisherLIPPINCOTT WILLIAMS & WILKINS
dc.relation.ispartofMEDICINE
dc.rightsopenAccess
dc.subjectadvanced protein oxidation products
dc.subjectbreast cancer
dc.subjectcolon cancer
dc.subjectischemia modified albumin
dc.subjectmalondialdehyde
dc.subjectnitric oxide
dc.subjectprooxidant-antioxidant balance
dc.subjecttotal antioxidant capacity
dc.subjectISCHEMIA-MODIFIED ALBUMIN
dc.subjectPROTEIN PRODUCTS
dc.subjectMARKER
dc.subjectTHIOREDOXIN
dc.subjectCARBONYL
dc.subjectRISK
dc.subjectGeneral & Internal Medicine
dc.titleThe evaluation of oxidative stress parameters in breast and colon cancer
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar